Beyond Companion Diagnostics: How Liquid Biopsy is Transforming Phase 1 Clinical Decision-Making
- Discover how biopharma teams are leveraging Guardant Health’s liquid biopsy platform earlier in development to accelerate Phase 1 insights and optimize trial strategy
- Explore the utility of non-destructive methylation profiling, tumor fraction assessment, and methylation signatures for advancing translational insights in Phase 1 oncology trials
- Learn through real-world case studies how ctDNA and molecular profiling informed dosing, patient selection, and early signal detection